FDA Not More Conservative Than EU, Jenkins Says; Investors Not Convinced
Executive Summary
Perceptions that FDA is more conservative in its approval standards than its European regulatory counterpart are misguided and largely overblown, Office of New Drugs Director John Jenkins said
You may also be interested in...
FDA, EMA Confidentiality Agreement Expanding Into "Clusters"
The "chatter" between reviewers and scientists at FDA and the European Medicines Agency appears to be increasing as the two bodies move toward renewing their confidential information sharing agreement
FDA, EMA Confidentiality Agreement Expanding Into "Clusters"
The "chatter" between reviewers and scientists at FDA and the European Medicines Agency appears to be increasing as the two bodies move toward renewing their confidential information sharing agreement
"Lagging Indicators": Is There A "Drug Lag" Between U.S. And Europe?
The "drug lag" is back. The term - biopharma industry shorthand for the belief that new drugs reach the market faster in other countries (especially in Europe) than they do the in U.S. - was a common refrain in the late 1980s and early 1990s, and the Prescription Drug User Fee Act of 1992 was intended in part to address the perception that U.S. consumers suffered while FDA reviews dragged on